Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657637 | 1.00 | PABPC1 (0.38) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL13822438 | 0.79 | PABPC1 (0.38) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL13392789 | 0.79 | PABPC1 (0.38) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL13822359 | 0.79 | PABPC1 (0.38) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL13822461 | 0.79 | PABPC1 (0.38) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL17190305 | 0.79 | PABPC1 (0.38) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL9378874 | 0.76 | PABPC1 (0.36) | PABPC1CTDSP1GAAHTR1AADRA1D | |
| SCHEMBL2657009 | 0.75 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL2655897 | 0.75 | PABPC1 (0.35) | PABPC1CTDSP1GAA | |
| SCHEMBL15700860 | 0.75 | PABPC1 (0.35) | PABPC1CTDSP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3878451-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND | Array Biopharma Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-109476643-B | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | 伊莱利利公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3484875-B1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3227297-B1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-107614496-B | Process for preparing aminotetrahydropyran compounds | 意大利合成制造有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3271344-B1 | PROCESS FOR PREPARING AMINOTETRAHYDROPYRANS | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2020-08-26 | — | — | EP | disclosed |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-2209778-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010049947-A2 | PREPARATION OF GEMCITABINE AND INTERMEDIATES THEREOF | ACCRETE PHARMACEUTICAL PRIVATE LIMITED (IN) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009042435-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
| EP-1615937-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092188-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291039-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | PABPC1 2036/4885CTDSP1 2257/4885GAA 4513/4885 |
| US-10730880-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | JAK1, JAK3, JAK2 | PABPC1 2036/4885CTDSP1 2257/4885GAA 4513/4885 |
| US-11028093-B2 | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | JAK1, JAK3, JAK2 | PABPC1 2036/4885CTDSP1 2257/4885GAA 4513/4885 |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | PABPC1 1772/4885CTDSP1 2724/4885GAA 1145/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | PABPC1 3964/4885CTDSP1 3997/4885GAA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.